However, TET2 mutations are relatively common in myeloid cancers [42] and are present in 20–25% of MDS, 7–23% of AML, and up to 53% of chronic myelomonocytic leukemia (CMML) patients [114, 115, 116]. This evidence concerns the gene TET2 and chronic myelomonocytic leukemia.